Biotech News
Related news
ELVNEnliven Therapeutics2026-06-15 20:40 EST
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
ELVNEnliven Therapeutics2026-06-12 02:39 EST
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
RVMDRevolution Medicines2026-07-29 20:05 EST
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
IMVTImmunovant2026-07-23 20:05 EST
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
IMTXImmatics2026-07-17 14:25 EST
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
CLDXCelldex Therapeutics2026-06-14 09:15 EST
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
LYELLyell Immunopharma2026-06-04 20:05 EST
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
REGNRegeneron Pharmaceuticals2026-06-04 11:00 EST
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
SNDXSyndax Pharmaceuticals2026-06-01 11:00 EST
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
REPLReplimune Group2026-05-31 12:00 EST
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Vaccinex
Vaccinex is a biotechnology company focused on antibody therapies and immunology, with a history of pursuing difficult oncology and neurodegenerative targets. Its story is tied to platform science and the challenge of turning it into durable value.
Recent company news
VCNXVaccinex2026-04-30 00:05 EST
Vaccinex Reports 2025 Annual Financial Results
VCNXVaccinex2025-12-23 13:01 EST
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
VCNXVaccinex2025-05-27 12:45 EST
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
VCNXVaccinex2025-04-21 12:45 EST
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
VCNXVaccinex2025-03-07 22:15 EST
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
Stock data
- Close
- 0.78 USD
- Market cap
- —
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States